ReviewCurrent opinion in rheumatology2012
Racial differences between blacks and whites with systemic sclerosis.
Review in Current opinion in rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.Arthritis care & research · 2024Guideline
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.Arthritis & rheumatology (Hoboken, N.J.) · 2024Guideline
- Association between systemic sclerosis and risk of cerebrovascular and cardiovascular disease: a meta-analysis.Scientific reports · 2024Pooled it
- Systemic sclerosis and risk of cardiovascular disease: A PRISMA-compliant systemic review and meta-analysis of cohort studies.Medicine · 2020Pooled it
- Revolutionizing Autoimmune Research: The Role of Caveolin-1.Immunity, inflammation and disease · 2025Review
- A Practical Multidisciplinary Approach to Identifying Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: A Clinician's Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- First Characterization of the Transcriptome of Lung Fibroblasts of SSc Patients and Healthy Donors of African Ancestry.International journal of molecular sciences · 2023Article
- Worsening premature death burden gap from systemic sclerosis in men and black persons: A US nationwide population-based study.Journal of scleroderma and related disorders · 2023Article
- Differences in synovial fibrosis relative to range of motion in knee osteoarthritis patients.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022Article
- Increased Mortality in Asians With Systemic Sclerosis in Northern California.ACR open rheumatology · 2020Article
- Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.Clinical rheumatology · 2020Article
- Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer.Cancers · 2019Review
- Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.Journal of scleroderma and related disorders · 2019Article
- Caveolin-1 as a target in prevention and treatment of hypertrophic scarring.NPJ Regenerative medicine · 2019Review
- Ethnic differences in TGFβ-signaling pathway may contribute to prostate cancer health disparity.Carcinogenesis · 2018Article
- Article
- Interstitial lung disease in systemic sclerosis: current and future treatment.Rheumatology international · 2017Review
- Deficient Adipogenesis of Scleroderma Patient and Healthy African American Monocytes.Frontiers in pharmacology · 2017Article
- Article
- Management of Systemic-Sclerosis-Associated Interstitial Lung Disease.Rheumatic diseases clinics of North America · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewRacial disparities appear to exist in the susceptibility and severity of systemic sclerosis (SSc, scleroderma) and are responsible for a greater health burden in blacks as compared with whites. Disparities in socioeconomic status and access to healthcare do not sufficiently explain the observed differences in prevalence and mortality. It is important to determine whether there might be a biologic basis for the racial disparities observed in SSc. RECENT
findingsWe present data to suggest that the increased susceptibility and severity of SSc in blacks may result in part from an imbalance of profibrotic and antifibrotic factors. Racial differences in the expression of transforming growth factor-β1 (TGF-β1) and caveolin-1, as well as differences in the expression of hepatocyte growth factor and PPAR-γ, have been demonstrated in blacks with SSc, as well as in normal black individuals. A genetic predisposition to fibrosis may account for much of the racial disparities between black and white patients with SSc. SUMMARY: A better understanding of the biologic basis for the racial disparities observed in SSc may lead to improved therapies, along with the recognition that different therapies may need to be adapted for different groups of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.